^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ASP0739

    i
    Other names: ASP0739, artificial adjuvant vector cells, NY-ESO-1 loaded artificial adjuvant vector cell
    Associations

    News

    Trials
    Company:
    Astellas, Riken
    Drug class:
    Cell replacement
    Related drugs:
    Associations

    News

    Trials
    3ms
    Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression Participants (clinicaltrials.gov)
    P1/2, N=16, Terminated, Astellas Pharma Global Development, Inc. | Completed --> Terminated; The comprehensive assessment of other studies indicated the lack of significant monotherapy activity, therefore, team decided to terminate the study.
    Trial termination • Combination therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1) • CTAG1B (Cancer/testis antigen 1B) • SSX1 (SSX Family Member 1)
    |
    Keytruda (pembrolizumab) • ASP0739
    over1year
    Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression Participants (clinicaltrials.gov)
    P1/2, N=16, Completed, Astellas Pharma Global Development, Inc. | Active, not recruiting --> Completed | N=339 --> 16 | Trial completion date: Jul 2024 --> May 2023 | Trial primary completion date: Jul 2024 --> May 2023
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1) • CTAG1B (Cancer/testis antigen 1B) • SSX1 (SSX Family Member 1)
    |
    CTAG1B expression
    |
    Keytruda (pembrolizumab) • ASP0739
    over1year
    Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression Participants (clinicaltrials.gov)
    P1/2, N=339, Active, not recruiting, Astellas Pharma Global Development, Inc. | Trial completion date: Jan 2028 --> Jul 2024 | Trial primary completion date: Jan 2026 --> Jul 2024
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1) • CTAG1B (Cancer/testis antigen 1B) • SSX1 (SSX Family Member 1)
    |
    CTAG1B expression
    |
    Keytruda (pembrolizumab) • ASP0739
    almost2years
    Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression Participants (clinicaltrials.gov)
    P1/2, N=339, Active, not recruiting, Astellas Pharma Global Development, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed • Combination therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1) • CTAG1B (Cancer/testis antigen 1B) • SSX1 (SSX Family Member 1)
    |
    CTAG1B expression
    |
    Keytruda (pembrolizumab) • ASP0739
    almost3years
    Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression Participants (clinicaltrials.gov)
    P1/2, N=339, Recruiting, Astellas Pharma Global Development, Inc. | Initiation date: Oct 2021 --> Jan 2022
    Trial initiation date • Combination therapy
    |
    PD-L1 (Programmed death ligand 1) • CTAG1B (Cancer/testis antigen 1B) • SSX1 (SSX Family Member 1)
    |
    CTAG1B expression
    |
    Keytruda (pembrolizumab) • ASP0739
    3years
    Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression Participants (clinicaltrials.gov)
    P1/2, N=339, Recruiting, Astellas Pharma Global Development, Inc. | Not yet recruiting --> Recruiting
    Clinical • Enrollment open • Combination therapy
    |
    PD-L1 (Programmed death ligand 1) • CTAG1B (Cancer/testis antigen 1B) • SSX1 (SSX Family Member 1)
    |
    CTAG1B expression
    |
    Keytruda (pembrolizumab) • ASP0739
    3years
    Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression Participants (clinicaltrials.gov)
    P1/2, N=339, Not yet recruiting, Astellas Pharma Global Development, Inc. | Trial primary completion date: Jul 2024 --> Jan 2026
    Clinical • Trial primary completion date • Combination therapy
    |
    PD-L1 (Programmed death ligand 1) • CTAG1B (Cancer/testis antigen 1B) • SSX1 (SSX Family Member 1)
    |
    CTAG1B expression
    |
    Keytruda (pembrolizumab) • ASP0739
    over3years
    Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression Participants (clinicaltrials.gov)
    P1/2, N=339, Not yet recruiting, Astellas Pharma Global Development, Inc.
    Clinical • New P1/2 trial • Combination therapy
    |
    PD-L1 (Programmed death ligand 1) • CTAG1B (Cancer/testis antigen 1B) • SSX1 (SSX Family Member 1)
    |
    CTAG1B expression
    |
    Keytruda (pembrolizumab) • ASP0739